Pham Quang X 4

What Happened Quang Pham, a 10% owner of Cadrenal Therapeutics (CVKD) and trustee of The PVBQ Living Trust, sold 7,400 shares of the company's common stock in open-market transactions on June 29, 2026. The reported weighted-average sale price was $3.03 per share for total proceeds of $22,422. This was a sale (not a purchase or award).

Key Details

• Transaction date: 2026-06-29; filing date: 2026-07-01 (Form 4 accession 0001213900-26-074557).
• Shares sold: 7,400; reported weighted-average price: $3.03; total proceeds: $22,422.
• Price range: shares were sold at prices between $3.00 and $3.13; the filer will provide per-price breakdown on request (footnote).
• Plan/authorization: Sales were made under a Rule 10b5-1 trading plan adopted by the reporting person on September 25, 2025.
• Ownership/authority: Quang Pham is trustee of The PVBQ Living Trust and has sole voting and dispositive power over the trust’s shares; the trust’s sole beneficiary is his child.
• Shares owned after the transaction: not specified in the provided excerpt.

Context This was a pre-arranged sale under a 10b5-1 plan, which typically means the trades were scheduled in advance and are routine rather than spontaneous insider sales. As a 10% owner and trustee (not listed here as an executive officer), Pham’s trade should be viewed differently than company-management trading; the filing is factual and does not indicate the filer’s motives.